Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Jaguar Health Inc (JAGX)

Jaguar Health Inc (JAGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,425
  • Shares Outstanding, K 4,905
  • Annual Sales, $ 9,760 K
  • Annual Income, $ -41,300 K
  • 60-Month Beta 0.83
  • Price/Sales 1.26
  • Price/Cash Flow N/A
  • Price/Book 0.58
Trade JAGX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -22.89
  • Growth Rate Est. (year over year) +4,464.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +21.90%
on 09/19/24
1.4100 -9.22%
on 09/30/24
+0.1600 (+14.29%)
since 09/04/24
3-Month
0.9501 +34.72%
on 08/13/24
4.4300 -71.11%
on 07/22/24
-2.2200 (-63.43%)
since 07/03/24
52-Week
0.9501 +34.72%
on 08/13/24
31.7400 -95.97%
on 10/12/23
-13.1200 (-91.11%)
since 10/04/23

Most Recent Stories

More News
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

FDA-approved Gelclair® is company's third commercialized prescription product

JAGX : 1.2800 (-2.29%)
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

FDA-approved Gelclair® is company's third commercialized prescription product

JAGX : 1.2800 (-2.29%)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.2800 (-2.29%)
Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.2800 (-2.29%)
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.2800 (-2.29%)
Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

New patent issued for core rare disease target indication for crofelemer

JAGX : 1.2800 (-2.29%)
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024

JAGX : 1.2800 (-2.29%)
Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024

JAGX : 1.2800 (-2.29%)
Jaguar Health Reports First Quarter 2024 Financial Results

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately...

JAGX : 1.2800 (-2.29%)
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II

Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track

JAGX : 1.2800 (-2.29%)

Business Summary

Jaguar Health, Inc. is a natural-products pharmaceuticals company. It focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals. The company through its subsidiary Napo Pharmaceuticals Inc., focuses on developing and commercializing...

See More

Key Turning Points

3rd Resistance Point 1.4733
2nd Resistance Point 1.4367
1st Resistance Point 1.3733
Last Price 1.2800
1st Support Level 1.2733
2nd Support Level 1.2367
3rd Support Level 1.1733

See More

52-Week High 31.7400
Fibonacci 61.8% 19.9783
Fibonacci 50% 16.3451
Fibonacci 38.2% 12.7118
Last Price 1.2800
52-Week Low 0.9501

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar